These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31718777)

  • 1. [The fatty liver epidemic: An analysis from the primary care].
    Caballeria L; Torán P
    Aten Primaria; 2019 Nov; 51(9):525-526. PubMed ID: 31718777
    [No Abstract]   [Full Text] [Related]  

  • 2. Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches.
    Pan Q; Fan JG
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):1-3. PubMed ID: 30611667
    [No Abstract]   [Full Text] [Related]  

  • 3. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease.
    Mandelia C; Kabbany MN; Conjeevaram Selvakumar PK; Alkhouri N
    Biomark Med; 2018 Mar; 12(3):265-273. PubMed ID: 29517271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease.
    Maurice J; Manousou P
    Clin Med (Lond); 2018 Jun; 18(3):245-250. PubMed ID: 29858436
    [TBL] [Abstract][Full Text] [Related]  

  • 7.  Estimated time from clinical presentation to the development of cirrhosis in non-cirrhotic adult patients with non-alcoholic fatty liver disease.
    Minuk GY; Sanders J; O'Brien M; Uhanova J
    Ann Hepatol; 2016 Nov-Dec 2016; 15(6):944-945. PubMed ID: 27740531
    [No Abstract]   [Full Text] [Related]  

  • 8. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
    Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
    Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions.
    Loomba R
    J Hepatol; 2018 Feb; 68(2):296-304. PubMed ID: 29203392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives.
    Festi D; Schiumerini R; Marasco G; Scaioli E; Pasqui F; Colecchia A
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1039-53. PubMed ID: 25993881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.
    Verna EC
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):211-223. PubMed ID: 28404136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
    Alkhouri N; Feldstein AE
    Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease.
    Sinha R; Lockman KA
    Aliment Pharmacol Ther; 2016 Jan; 43(1):163. PubMed ID: 26638929
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease.
    Patel V; Sanyal AJ; Sterling R
    Clin Liver Dis; 2016 May; 20(2):277-92. PubMed ID: 27063269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
    Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health].
    Vallet-Pichard A; Parlati L; Pol S
    Presse Med; 2019 Dec; 48(12):1459-1467. PubMed ID: 31757728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
    Yopp AC; Choti MA
    Dig Dis; 2015 Sep; 33(5):642-7. PubMed ID: 26398208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-alcoholic fatty liver: position document of the Catalan Society of Gastroenterology].
    Caballería L; Saló J; Berzigotti A; Planas R; Vila C; Huertas C; Torres M; Torán P; Caballería J;
    Gastroenterol Hepatol; 2014; 37(6):372-83. PubMed ID: 24746904
    [No Abstract]   [Full Text] [Related]  

  • 20. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.